Core Viewpoint - Furuya Medical Technology (01696.HK) has announced that its reauthorized injectable botulinum toxin type A (DaxibotulinumtoxinA-lanm, trademarked as 达希斐® in China and DAXXIFY® in English) has passed quality standard inspections by the China National Institute for Food and Drug Control, marking a significant step towards commercialization in China [1] Group 1 - The product is intended for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults [1] - As of the announcement date, there are no other DaxibotulinumtoxinA products available for sale in China, indicating a first-mover advantage for the company [1] - The successful inspection signifies that DaxibotulinumtoxinA has met the stringent quality, safety, and efficacy requirements set by Chinese regulatory authorities [1] Group 2 - The company has secured its first commercial orders for DaxibotulinumtoxinA in the Chinese market, officially entering the commercialization phase [1] - DaxibotulinumtoxinA is viewed as a strategic cornerstone for the company's injectable filler business, enhancing product diversity and providing more quality options for consumers [1] - The product is expected to serve as a second growth engine, contributing to sustained consumable revenue and reinforcing the company's leading position in the global beauty and health industry [1]
复锐医疗科技(01696.HK)旗下获再授权注射用A型肉毒毒素已通过中国食品药品检定研究院质量标准检验